{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:41:00Z","timestamp":1792518060311,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02926-8","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:01:58Z","timestamp":1792364518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kegang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"2926_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt, E., Salles, G., Campo, E. & Dreyling, M. B-cell non-Hodgkin lymphomas. Lancet 403, 1791\u20131807 (2024).","journal-title":"Lancet"},{"key":"2926_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cpt.2022.09.006","volume":"1","author":"Y Shi","year":"2023","unstructured":"Shi, Y. et al. Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018). Cancer Pathog. Ther. 1, 3\u201311 (2023).","journal-title":"Cancer Pathog. Ther."},{"key":"2926_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11876-9","volume":"24","author":"Y Qin","year":"2024","unstructured":"Qin, Y. et al. Long-term outcomes with HLX01 (HanliKang), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study. BMC Cancer 24, 124 (2024).","journal-title":"BMC Cancer"},{"key":"2926_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/cac2.12126","volume":"41","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. Cancer Commun. 41, 229\u2013239 (2021).","journal-title":"Cancer Commun."},{"key":"2926_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste, E. et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transpl. 51, 51\u201357 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"2926_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s43018-024-00777-2","volume":"5","author":"NW Mabe","year":"2024","unstructured":"Mabe, N. W., Perry, J. A., Malone, C. F. & Stegmaier, K. Pharmacological targeting of the cancer epigenome. Nat. Cancer 5, 844\u2013865 (2024).","journal-title":"Nat. Cancer"},{"key":"2926_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","volume":"19","author":"N Vasan","year":"2022","unstructured":"Vasan, N. & Cantley, L. C. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signaling into improvements in cancer therapy. Nat. Rev. Clin. Oncol. 19, 471\u2013485 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2926_CR8","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","volume":"62","author":"K Zhang","year":"2019","unstructured":"Zhang, K. et al. Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases. J. Med. Chem. 62, 6992\u20137014 (2019).","journal-title":"J. Med. Chem."},{"key":"2926_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116015","volume":"264","author":"K Zhang","year":"2024","unstructured":"Zhang, K. et al. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K\/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur. J. Med. Chem. 264, 116015 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2926_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11523-023-01006-z","volume":"18","author":"N Wang","year":"2023","unstructured":"Wang, N. et al. Dual PI3K\/HDAC inhibitor BEBT-908 exhibits potent efficacy as monotherapy for primary central nervous system lymphoma. Target Oncol. 18, 941\u2013952 (2023).","journal-title":"Target Oncol."},{"key":"2926_CR11","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","volume":"81","author":"F Fan","year":"2021","unstructured":"Fan, F. et al. A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy. Cancer Res. 81, 6233\u20136245 (2021).","journal-title":"Cancer Res."},{"key":"2926_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi, M. Q. et al. Advances in targeting histone deacetylase for treatment of solid tumors. J. Hematol. Oncol. 17, 37 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2926_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cmdc.202000643","volume":"16","author":"DA Rodrigues","year":"2021","unstructured":"Rodrigues, D. A., Pinheiro, P. S. M. & Fraga, C. A. M. Multitarget inhibition of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K): current and future prospects. ChemMedChem. 16, 448\u2013457 (2021).","journal-title":"ChemMedChem"},{"key":"2926_CR14","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","volume":"20","author":"M Rahmani","year":"2014","unstructured":"Rahmani, M. et al. PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin. Cancer Res. 20, 4849\u20134860 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2926_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjh.17792","volume":"196","author":"K Fjorden","year":"2022","unstructured":"Fjorden, K. et al. Idelalisib in relapsed\/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. Br. J. Haematol. 196, 437\u2013440 (2022).","journal-title":"Br. J. Haematol."},{"key":"2926_CR16","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz, G. et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 34, 2184\u20132197 (2020).","journal-title":"Leukemia"},{"key":"2926_CR17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdn031","volume":"19","author":"M Crump","year":"2008","unstructured":"Crump, M. et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 19, 964\u2013969 (2008).","journal-title":"Ann. Oncol."},{"key":"2926_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes, A. et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 17, 622\u2013631 (2016).","journal-title":"Lancet Oncol."},{"key":"2926_CR19","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicenter, open-label, phase 2 trial. Lancet Haematol. 7, e511\u2013e522 (2020).","journal-title":"Lancet Haematol."},{"key":"2926_CR20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2926_CR21","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicenter, single-arm, phase 2 trial. Lancet Haematol. 6, e12\u2013e19 (2019).","journal-title":"Lancet Haematol."},{"key":"2926_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2926_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla, J. et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicenter, randomized, open-label, phase 3 study. Lancet Oncol. 22, 512\u2013524 (2021).","journal-title":"Lancet Oncol."},{"key":"2926_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02926-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02926-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02926-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:51Z","timestamp":1792515711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02926-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02926-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yajie Cao, Yonglong Yang, Kegang Jiang, and Changgeng Qian are employees of BeBetter Med Inc., Guangzhou, Guangdong, P. R. China. All other authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"466"}}